To further identify more novel predictive biomarkers, we performed data analysis using several public cohorts and found that MAP2K1/2 mutations might be a potential predictor for the clinical benefits of anti-CTLA-4 therapy in advanced melanomas. Here, MAP2K1 is linked to melanoma.